scholarly journals Predominant subtype of heart failure after acute myocardial infarction is heart failure with non‐reduced ejection fraction

2020 ◽  
Author(s):  
Daisuke Kamon ◽  
Yu Sugawara ◽  
Tsunenari Soeda ◽  
Akihiko Okamura ◽  
Yasuki Nakada ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Ejection Fraction ◽  
Reduced Ejection Fraction ◽  
Predominant Subtype

scholarly journals Carvedilol versus metoprolol succinate in the treatment of patients with heart failure with reduced ejection fraction and patients with acute myocardial infarction

2021 ◽  
Vol 2021 (1) ◽  
pp. 36-39
Author(s):  
E.Ya. Nikolenko ◽  
◽  
K.V. Vovk ◽  
O.L. Pavlova ◽  
O.O. Salun ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Ejection Fraction ◽  
Randomized Trials ◽  
Meta Analysis ◽  
Metoprolol Succinate ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure ◽  
All Cause Mortality

Choosing the best drug for the treatment of cardiac patients remains one of the most important aspects of medical practice. The purpose of this review is to select the optimal beta-blocker for the treatment of patients with chronic heart failure and patients with acute myocardial infarction by comparing the efficacy of carvedilol and metoprolol succinate, as both drugs significantly reduce mortality rates and reduce hospitalization. The results of meta-analyzes, randomized trials comparing the efficacy of carvedilol and metoprolol succinate in the treatment of patients with heart failure with reduced ejection fraction and patients with acute myocardial infarction were analyzed. Conflicting data received. According to the study “Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction”, a meta-analysis published in the American Journal of Cardiology in 2013, carvedilol is significantly more effective than metoprolol succinate in treatment of patients with heart failure with reduced ejection fraction and patients with acute myocardial infarction, while meta-analyzes of 2015 and 2017 showed no preference for carvedilol over metoprolol succinate. Based on the results, concluded that the data obtained is not sufficient to argue that carvedilol is more effective than metoprolol succinate for this category of patients in terms of reducing the risk of all-cause mortality, cardiovascular mortality, and reducing hospitalization. This problem requires further extensive research.

scholarly journals Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction

2017 ◽  
Vol 10 (2) ◽  
Author(s):  
João Pedro Ferreira ◽  
Nicolas Girerd ◽  
Kevin Duarte ◽  
Stefano Coiro ◽  
John J. V. McMurray ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Ejection Fraction ◽  
Reduced Ejection Fraction ◽  
Serum Chloride

Abstract 17371: In-Hospital Outcomes of Ablation for Ventricular Tachycardia in Heart Failure With Reduced Ejection Fraction

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Raj Patel ◽  
Dipesh Ludhwani ◽  
Harsh P Patel ◽  
Samarthkumar J Thakkar ◽  
Love shah ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Ventricular Tachycardia ◽  
Catheter Ablation ◽  
Ejection Fraction ◽  
Reference Group ◽  
Coronary Bypass ◽  
Reference Population ◽  
Reduced Ejection Fraction ◽  
Vt Ablation

Introduction: Ventricular tachycardia (VT) is a significant cause of morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF). Hypothesis: Data on efficacy, safety, and outcomes of catheter ablation for VT in HFrEF have not been studied well. Methods: The 2002-2014 Nationwide Inpatient Sample (NIS) was used to identify all hospitalizations with a principle diagnosis of VT (International Classification of Diseases, Ninth Edition, Clinical Modification [ICD-9-CM] code 427.1) and a secondary diagnosis of HFrEF. Patients who underwent catheter ablation were identified using ICD-9-CM procedure code 37.34. Results: Of 228,557 patients with HFrEF & VT, 5845 (2.56%) underwent catheter ablation. The prevalence of Diabetes Mellitus (DM) and Chronic Kidney disease (CKD) was higher in the reference population contrary to a higher prevalence of prior myocardial infarction (MI), coronary bypass and AICD in those undergoing CA. The frequency of complications in the ablation group was 19.47%, the most common being post-operative hemorrhage (8.3%). This was followed by myocardial infarction (5.34%), pericardial complications (3.38%), and neurological complications (2.14%) (Figure 1.). The odds of in-hospital mortality were lower in the CA group compared to the reference group (5.08% vs 9.42%, p<0.05). Conclusions: Compared to medical therapy, VT ablation in HFrEF is associated with lower mortality though with significant complication rate. This suggests a need for future studies identifying the safety measures in VT ablations and instituting appropriate interventions to improve overall VT ablation outcomes.

scholarly journals Prognostic value of D‐dimer in acute myocardial infarction complicated by heart failure with preserved ejection fraction

2020 ◽  
Vol 7 (6) ◽  
pp. 4118-4125
Author(s):  
Xiaoyuan Zhang ◽  
Shanjie Wang ◽  
Liping Sun ◽  
Shaohong Fang ◽  
Bo Yu
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Ejection Fraction ◽  
Prognostic Value ◽  
Preserved Ejection Fraction ◽  
D Dimer

Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry

2020 ◽  
Vol 27 (17) ◽  
pp. 1890-1901 ◽  
Author(s):  
Viveca Ritsinger ◽  
Thomas Nyström ◽  
Nawsad Saleh ◽  
Bo Lagerqvist ◽  
Anna Norhammar
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Left Ventricular Ejection Fraction ◽  
Ejection Fraction ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Common Complication ◽  
Ventricular Ejection Fraction ◽  
Patients With Diabetes

Background Several glucose lowering drugs with preventive effects on heart failure and death have entered the market, however, still used in low proportions after acute myocardial infarction. We explored the complication rates of heart failure and death after acute myocardial infarction in patients with and without diabetes. Methods All patients ( N = 73,959) with acute myocardial infarction admitted for coronary angiography included in the SWEDEHEART registry during the years 2012–2017 were followed for heart failure (until 31 December 2017) and mortality (until 30 June 2018); mean follow-up time 1223 (SD ± 623) days. Results Mean age was 69 years (SD ± 12), 69% were male and 24% had diabetes. Heart failure occurred more often in diabetes (22% vs. 12% if no diabetes), especially if previous MI (33% vs. 23%). Patients with diabetes had increased risk of HF regardless of previous myocardial infarction (MI); with previous MI adjusted hazard ratio 2.09 (95% confidence interval 1.96–2.20) and without MI 1.52 (1.44–1.61) respectively when non-diabetes patients with first MI served as reference. In patients with no previous heart failure or MI and discharged with left ventricular ejection fraction ≥50% the risk of heart failure was particularly high in those with diabetes (1.56; 1.39–1.76) when compared with those without. Similar findings were seen for death and combined event (heart failure and death). Conclusions Heart failure is a common complication after acute myocardial infarction in diabetes, increasing the risk by 50–60% regardless of previous heart failure or MI. This risk is present even with normal reported left ventricular ejection fraction, indicating the existence of a large diabetes population at heart failure risk after acute myocardial infarction.

Is Reduced Ejection Fraction an Obstacle for Adherence to Cardiac Rehabilitation in Elderly Patients After Acute Myocardial Infarction?

2007 ◽  
Vol 13 (6) ◽  
pp. S58
Author(s):  
Yuichi Adachi ◽  
Harumi Konishi ◽  
Atsuko Maruji ◽  
Kayoko Kobayashi ◽  
Saori Kusunoki ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Ejection Fraction ◽  
Elderly Patients ◽  
Cardiac Rehabilitation ◽  
Reduced Ejection Fraction

scholarly journals A prolonged follow-up of patients with acute myocardial infarction with using aldosterone antagonists

2013 ◽  
Vol 17 (2 (66)) ◽  
pp. 132-136
Author(s):  
V. K. Tashchuk ◽  
O. S. Polianska ◽  
O. I. Gulaga
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Left Ventricle ◽  
Ejection Fraction ◽  
Functional Condition ◽  
Plasma Aldosterone ◽  
Aldosterone Antagonists ◽  
S Factor

We have carried out an analysis of longterm results of using aldosterone antagonists (spironolactone and eplerenone) in a holiatry of patients with myocardial infacrtion and heart failure. The functional condition of the myocardium has been investigated by means of electrocardiography, the level of the neurohumoral messengers – aldosterone, angiotensin-converting enzym, atrial natriuretic peptide, Willebrand`s factor has been determined. It has been demonstrated that with the use of eplerenone there exists a higher probability of restoring the functional state of the myocardium in patients – an increase of the ejection fraction by 16,1 %, the stroke volume by 23,2 %. According to the theory of chances it has been established that, while using eplerenone, the likelihood of achieving the mass of the myocardium of the left ventricle less than 180,24±15,24 g is sighnificantly higher than the use of spironolactone (t=2,10, р<0,05). While analyzing the concentration of the blood plasma aldosterone it was establishes that in a year its content essentially decreased in both groups, although it was more marked in persons who took eplerenone (р<0,01).

Sign in / Sign up

Export Citation Format

Share Document